In England's final Test against New Zealand, Kevin Pietersen will not be seen as the England batsman has been ruled out for next six to seven weeks because of knee injury.
Pieterson has joined bowlers; spinner Graeme Swann and seamer Tim Bresnan as a long-term absentee after the pair both had undergone surgery for elbow injuries.
The 32-year-old will not play the match. He is also expected to stay out from next month's Indian Premier League (IPL) where he was supposed to play with Delhi Daredevils. The IPL is scheduled to start on 3 April.
The Surrey player was reported to have knee pain while fielding in the warm-up match in Queenstown at the start of the month. The problem perpetuated because of which he had to spent time off the field in the first test of Dunedin.
After this he was taken for medical check where his knee was scanned. The reports confirmed an injury to the knee, with bone bruising and possible cartilage damage to the kneecap.
Pietersen will now return to the UK for further tests and has been asked to accompany medical examination with rest. Experts say that he will have to take an off from the field for at least six weeks.
According to a post published to Microsoft’s official blog on Wednesday, the number of devices running the company’s latest Windows version -- the Windows 10 operating system -- has touched 350 million.
The new milestone in the Windows 10...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
During the course of Thursday proceedings in the ongoing legal scuffle between Google and Oracle...
The Verge has revealed in a Wednesday report, citing a statement released by Lexus, that the working of the head units of a number of vehicles has been affected because of an over-the-air (OTA) update recently rolled out by the company.
...
The drought conditions in California is widening economic split in California. The prospect of...
Tech giant Google posted a video of a developer presentation to the Google Developers YouTube...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
A panel of US medical experts said that there is no...
At the GSMA Mobile World Congress in Shanghai, HTV Vive...
According to a post published to Microsoft’s official...
No matter how dangerous a task it seems to look within a...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).